{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:23:07Z","timestamp":1789698187929,"version":"4.0.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["GMR23T2153"],"award-info":[{"award-number":["GMR23T2153"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2024 MoH"],"award-info":[{"award-number":["Ricerca Corrente 2024 MoH"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2018-12365358"],"award-info":[{"award-number":["GR-2018-12365358"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-49537-5","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:06:59Z","timestamp":1776870419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigating the role of serum NfL, FGF21, NCAM1 and GDF15 as disease biomarkers for Charcot-Marie-Tooth type 2A"],"prefix":"10.1038","volume":"16","author":[{"given":"Elena","family":"Abati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Saccomanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Anastasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Gagliardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Arosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"D Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Cima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Oldoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo Pietro","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania Paola","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"5","key":"49537_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/WCO.0000000000000735","volume":"32","author":"M Laur\u00e1","year":"2019","unstructured":"Laur\u00e1, M., Pipis, M., Rossor, A. M. & Reilly, M. M. Charcot-Marie-Tooth disease and related disorders: An evolving landscape. Curr. Opin. Neurol. 32(5), 641\u2013650. https:\/\/doi.org\/10.1097\/WCO.0000000000000735 (2019).","journal-title":"Curr. Opin. Neurol."},{"issue":"7","key":"49537_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/NEN.0b013e318220c69d","volume":"70","author":"SM Feely","year":"2011","unstructured":"Feely, S. M. et al. Charcot-Marie-Tooth disease 2A is the most frequent form of CMT2. J Neuropathol Exp Neurol. 70(7), 649\u2013657. https:\/\/doi.org\/10.1097\/NEN.0b013e318220c69d (2011).","journal-title":"J Neuropathol Exp Neurol."},{"key":"49537_CR3","doi-asserted-by":"publisher","first-page":"e210120","DOI":"10.1212\/WNL.0000000000210120","volume":"103","author":"BA McCray","year":"2024","unstructured":"McCray, B. A. & Fridman, V. Clinical outcome assessments and biomarkers in Charcot-Marie-Tooth Disease. Neurology 103, e210120. https:\/\/doi.org\/10.1212\/WNL.0000000000210120 (2024).","journal-title":"Neurology"},{"issue":"5","key":"49537_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/ng1341","volume":"36","author":"S Z\u00fcchner","year":"2004","unstructured":"Z\u00fcchner, S. et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat. Genet. 36(5), 449\u2013451. https:\/\/doi.org\/10.1038\/ng1341 (2004).","journal-title":"Nat. Genet."},{"issue":"Pt 8","key":"49537_CR5","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/brain\/awl025","volume":"129","author":"K Verhoeven","year":"2006","unstructured":"Verhoeven, K. et al. MFN2 mutation distribution and genotype\/phenotype correlation in Charcot-Marie-Tooth type 2. Brain 129(Pt 8), 2093\u20132102. https:\/\/doi.org\/10.1093\/brain\/awl025 (2006).","journal-title":"Brain"},{"issue":"12","key":"49537_CR6","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1001\/archneurol.2009.284","volume":"66","author":"J Calvo","year":"2009","unstructured":"Calvo, J. et al. Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations. Arch. Neurol. 66(12), 1511\u20131516. https:\/\/doi.org\/10.1001\/archneurol.2009.284 (2009).","journal-title":"Arch. Neurol."},{"issue":"2","key":"49537_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.expneurol.2009.05.003","volume":"218","author":"R Cartoni","year":"2009","unstructured":"Cartoni, R. & Martinou, J. C. Role of mitofusin 2 mutations in the physiopathology of Charcot-Marie-Tooth disease type 2A. Exp. Neurol. 218(2), 268\u2013273. https:\/\/doi.org\/10.1016\/j.expneurol.2009.05.003 (2009).","journal-title":"Exp. Neurol."},{"issue":"20","key":"49537_CR8","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1212\/WNL.0b013e31821a441e","volume":"76","author":"SME Feely","year":"2011","unstructured":"Feely, S. M. E. et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 76(20), 1690\u20131696. https:\/\/doi.org\/10.1212\/WNL.0b013e31821a441e (2011).","journal-title":"Neurology"},{"issue":"1-2","key":"49537_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neurol.2022.11.006","volume":"179","author":"S Beloribi-Djefaflia","year":"2023","unstructured":"Beloribi-Djefaflia, S. & Attarian, S. Treatment of Charcot-Marie-Tooth neuropathies. Rev Neurol (Paris) 179(1\u20132), 35\u201348. https:\/\/doi.org\/10.1016\/j.neurol.2022.11.006 (2023).","journal-title":"Rev Neurol (Paris)"},{"issue":"6386","key":"49537_CR10","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1126\/science.aao1785","volume":"360","author":"AG Rocha","year":"2018","unstructured":"Rocha, A. G. et al. MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. Science 360(6386), 336\u2013341. https:\/\/doi.org\/10.1126\/science.aao1785 (2018).","journal-title":"Science"},{"key":"49537_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/J.NBD.2024.106467","author":"C Alberti","year":"2024","unstructured":"Alberti, C. et al. Charcot-Marie-Tooth disease type 2A: An update on pathogenesis and therapeutic perspectives. Neurobiol. Dis. https:\/\/doi.org\/10.1016\/J.NBD.2024.106467 (2024).","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"49537_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1124\/jpet.122.001332","volume":"383","author":"A Franco","year":"2022","unstructured":"Franco, A. et al. Mitochondrial dysfunction and pharmacodynamics of mitofusin activation in murine Charcot-Marie-Tooth disease type 2A. J. Pharmacol. Exp. Ther. 383(2), 137\u2013148. https:\/\/doi.org\/10.1124\/jpet.122.001332 (2022).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"13","key":"49537_CR13","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.1021\/acs.jmedchem.0c00366","volume":"63","author":"X Dang","year":"2020","unstructured":"Dang, X. et al. Discovery of 6-phenylhexanamide derivatives as potent stereoselective mitofusin activators for the treatment of mitochondrial diseases. J. Med. Chem. 63(13), 7033\u20137051. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00366 (2020).","journal-title":"J. Med. Chem."},{"issue":"2","key":"49537_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1124\/jpet.124.002258","volume":"391","author":"J Weigele","year":"2024","unstructured":"Weigele, J. et al. Sensory-motor neuropathy in Mfn2 T105M knock-in mice and its reversal by a novel piperine-derived mitofusin activator. J. Pharmacol. Exp. Ther. 391(2), 361\u2013374. https:\/\/doi.org\/10.1124\/jpet.124.002258 (2024).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"49537_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13650","author":"AM Rossor","year":"2022","unstructured":"Rossor, A. M. & Reilly, M. M. Blood biomarkers of peripheral neuropathy. Acta Neurol Scand. https:\/\/doi.org\/10.1111\/ane.13650 (2022).","journal-title":"Acta Neurol Scand."},{"issue":"2","key":"49537_CR16","first-page":"122","volume":"14","author":"J Burns","year":"2012","unstructured":"Burns, J. et al. Patient outcome measures in Charcot-Marie-Tooth disease. Neuromolecul Med. 14(2), 122\u2013130 (2012).","journal-title":"Neuromolecul Med."},{"issue":"8","key":"49537_CR17","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry. 90(8), 870\u2013881. https:\/\/doi.org\/10.1136\/jnnp-2018-320106 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"25","key":"49537_CR18","doi-asserted-by":"publisher","first-page":"8501","DOI":"10.1523\/JNEUROSCI.1081-12.2012","volume":"32","author":"A Yuan","year":"2012","unstructured":"Yuan, A. et al. Peripherin is a subunit of peripheral nerve neurofilaments. J Neurosci. 32(25), 8501\u20138508. https:\/\/doi.org\/10.1523\/JNEUROSCI.1081-12.2012 (2012).","journal-title":"J Neurosci."},{"issue":"6","key":"49537_CR19","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","volume":"90","author":"\u00c5 Sandelius","year":"2018","unstructured":"Sandelius, \u00c5. et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology 90(6), e518\u2013e524. https:\/\/doi.org\/10.1212\/WNL.0000000000004932 (2018).","journal-title":"Neurology"},{"issue":"3","key":"49537_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/ENE.14689","volume":"28","author":"E Millere","year":"2021","unstructured":"Millere, E. et al. Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. Eur. J. Neurol. 28(3), 974\u2013991. https:\/\/doi.org\/10.1111\/ENE.14689 (2021).","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"49537_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/JNS.12477","volume":"27","author":"AM Rossor","year":"2022","unstructured":"Rossor, A. M. et al. A longitudinal and cross-sectional study of plasma neurofilament light chain concentration in Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 27(1), 50\u201357. https:\/\/doi.org\/10.1111\/JNS.12477 (2022).","journal-title":"J Peripher Nerv Syst."},{"issue":"3","key":"49537_CR22","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1212\/WNL.0000000000011090","volume":"96","author":"S Ticau","year":"2021","unstructured":"Ticau, S. et al. Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology 96(3), e412\u2013e422. https:\/\/doi.org\/10.1212\/WNL.0000000000011090 (2021).","journal-title":"Neurology"},{"issue":"8","key":"49537_CR23","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1111\/ENE.15858","volume":"30","author":"S Setlere","year":"2023","unstructured":"Setlere, S. et al. Plasma neurofilament light chain level is not a biomarker of Charcot-Marie-Tooth disease progression. Eur J Neurol. 30(8), 2453\u20132460. https:\/\/doi.org\/10.1111\/ENE.15858 (2023).","journal-title":"Eur J Neurol."},{"issue":"4","key":"49537_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/S10048-023-00729-5","volume":"24","author":"E Palu","year":"2023","unstructured":"Palu, E. et al. Rare PMP22 variants in mild to severe neuropathy uncorrelated to plasma GDF15 or neurofilament light. Neurogenetics 24(4), 291. https:\/\/doi.org\/10.1007\/S10048-023-00729-5 (2023).","journal-title":"Neurogenetics"},{"issue":"11","key":"49537_CR25","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1093\/BRAIN\/AWAC055","volume":"145","author":"MJ Jennings","year":"2022","unstructured":"Jennings, M. J. et al. NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice. Brain 145(11), 3999\u20134015. https:\/\/doi.org\/10.1093\/BRAIN\/AWAC055 (2022).","journal-title":"Brain"},{"issue":"6559","key":"49537_CR26","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/SCIENCE.ABB3414","volume":"373","author":"EL Spaulding","year":"2021","unstructured":"Spaulding, E. L. et al. The integrated stress response contributes to tRNA synthetase-associated peripheral neuropathy. Science 373(6559), 1156\u20131161. https:\/\/doi.org\/10.1126\/SCIENCE.ABB3414 (2021).","journal-title":"Science"},{"issue":"6","key":"49537_CR27","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/ENE.15763","volume":"30","author":"YH Kim","year":"2023","unstructured":"Kim, Y. H. et al. Neural cell adhesion molecule 1 is a cellular target engaged plasma biomarker in demyelinating Charcot-Marie-Tooth disease. Eur. J. Neurol. 30(6), 1745\u20131754. https:\/\/doi.org\/10.1111\/ENE.15763 (2023).","journal-title":"Eur. J. Neurol."},{"key":"49537_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/FNEUR.2024.1490024","volume":"15","author":"D Pretkalnina","year":"2025","unstructured":"Pretkalnina, D. et al. Evaluating plasma biomarkers NfL, GFAP, GDF15, and FGF21 as indicators of disease severity in Charcot-Marie Tooth patients. Front. Neurol. 15, 1490024. https:\/\/doi.org\/10.3389\/FNEUR.2024.1490024 (2025).","journal-title":"Front. Neurol."},{"key":"49537_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEUROT.2024.E00325","author":"BJ Shayota","year":"2024","unstructured":"Shayota, B. J. Biomarkers of mitochondrial disorders. Neurotherapeutics https:\/\/doi.org\/10.1016\/J.NEUROT.2024.E00325 (2024).","journal-title":"Neurotherapeutics"},{"issue":"1","key":"49537_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/JCMM.13952","volume":"23","author":"Y Lu","year":"2019","unstructured":"Lu, Y. et al. Fibroblast growth factor 21 facilitates peripheral nerve regeneration through suppressing oxidative damage and autophagic cell death. J. Cell. Mol. Med. 23(1), 497\u2013511. https:\/\/doi.org\/10.1111\/JCMM.13952 (2019).","journal-title":"J. Cell. Mol. Med."},{"issue":"11","key":"49537_CR31","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/nrm2275","volume":"8","author":"SA Detmer","year":"2007","unstructured":"Detmer, S. A. & Chan, D. C. Functions and dysfunctions of mitochondrial dynamics. Nat. Rev. Mol. Cell Biol. 8(11), 870\u2013879. https:\/\/doi.org\/10.1038\/nrm2275 (2007).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"49537_CR32","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1523\/JNEUROSCI.4798-06.2007","volume":"27","author":"RH Baloh","year":"2007","unstructured":"Baloh, R. H., Schmidt, R. E., Pestronk, A. & Milbrandt, J. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J. Neurosci. 27(2), 422\u2013430. https:\/\/doi.org\/10.1523\/JNEUROSCI.4798-06.2007 (2007).","journal-title":"J. Neurosci."},{"issue":"5","key":"49537_CR33","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/WCO.0000000000000474","volume":"30","author":"D Pareyson","year":"2017","unstructured":"Pareyson, D., Saveri, P. & Pisciotta, C. New developments in Charcot-Marie-Tooth neuropathy and related diseases. Curr. Opin. Neurol. 30(5), 471\u2013480. https:\/\/doi.org\/10.1097\/WCO.0000000000000474 (2017).","journal-title":"Curr. Opin. Neurol."},{"issue":"3","key":"49537_CR34","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1529-8027.2011.00350.x","volume":"16","author":"SM Murphy","year":"2011","unstructured":"Murphy, S. M. et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J. Peripher. Nerv. Syst. 16(3), 191\u2013198. https:\/\/doi.org\/10.1111\/j.1529-8027.2011.00350.x (2011).","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"7","key":"49537_CR35","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1212\/01.WNL.0000156517.00615.A3","volume":"64","author":"ME Shy","year":"2005","unstructured":"Shy, M. E. et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64(7), 1209\u20131214. https:\/\/doi.org\/10.1212\/01.WNL.0000156517.00615.A3 (2005).","journal-title":"Neurology"},{"issue":"4","key":"49537_CR36","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1172\/JCI124194","volume":"129","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model. J. Clin. Invest. 129(4), 1756\u20131771. https:\/\/doi.org\/10.1172\/JCI124194 (2019).","journal-title":"J. Clin. Invest."},{"issue":"13","key":"49537_CR37","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","volume":"87","author":"P Oeckl","year":"2016","unstructured":"Oeckl, P. et al. Serum neurofilament light chain is a biomarker for disease progression in ALS. Neurology 87(13), 1329\u20131336. https:\/\/doi.org\/10.1212\/WNL.0000000000003154 (2016).","journal-title":"Neurology"},{"issue":"10","key":"49537_CR38","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007096","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle, J. et al. Serum neurofilament light chain in neurological disorders. Neurology 92(10), e1007\u2013e1015. https:\/\/doi.org\/10.1212\/WNL.0000000000007096 (2019).","journal-title":"Neurology"},{"issue":"1","key":"49537_CR39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/S12881-015-0224-8","volume":"16","author":"T Antoniadi","year":"2015","unstructured":"Antoniadi, T. et al. Application of targeted multi-gene panel testing for the diagnosis of inherited peripheral neuropathy provides a high diagnostic yield. BMC Med Genet. 16(1), 84. https:\/\/doi.org\/10.1186\/S12881-015-0224-8 (2015).","journal-title":"BMC Med Genet."},{"issue":"8","key":"49537_CR40","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1111\/JCMM.16240","volume":"25","author":"D Gagliardi","year":"2021","unstructured":"Gagliardi, D. et al. Diagnostic and prognostic value of CSF neurofilaments in a cohort of patients with motor neuron disease. J Cell Mol Med. 25(8), 3765\u20133771. https:\/\/doi.org\/10.1111\/JCMM.16240 (2021).","journal-title":"J Cell Mol Med."},{"issue":"5","key":"49537_CR41","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1111\/JCMM.14939","volume":"24","author":"I Faravelli","year":"2020","unstructured":"Faravelli, I. et al. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients. J Cell Mol Med. 24(5), 3034\u20133039. https:\/\/doi.org\/10.1111\/JCMM.14939 (2020).","journal-title":"J Cell Mol Med."},{"key":"49537_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa323","author":"M Pipis","year":"2021","unstructured":"Pipis, M. et al. Natural history of Charcot-Marie-Tooth disease type 2A: A large international multicentre study. Brain https:\/\/doi.org\/10.1093\/brain\/awaa323 (2021).","journal-title":"Brain"},{"issue":"6","key":"49537_CR43","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrneurol.2015.77","volume":"11","author":"I Faravelli","year":"2015","unstructured":"Faravelli, I., Nizzardo, M., Comi, G. P. & Corti, S. Spinal muscular atrophy--recent therapeutic advances for an old challenge. Nat. Rev. Neurol. 11(6), 351\u2013359. https:\/\/doi.org\/10.1038\/nrneurol.2015.77 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"49537_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/BRAINCOMMS\/FCAE312","author":"E Abati","year":"2024","unstructured":"Abati, E. et al. Investigating the prevalence of MFN2 mutations in amyotrophic lateral sclerosis: Insights from an Italian cohort. Brain Commun. https:\/\/doi.org\/10.1093\/BRAINCOMMS\/FCAE312 (2024).","journal-title":"Brain Commun."},{"key":"49537_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/FNINS.2019.00601","author":"F Gentile","year":"2019","unstructured":"Gentile, F. et al. The peripheral nervous system in amyotrophic lateral sclerosis: Opportunities for translational research. Front. Neurosci. https:\/\/doi.org\/10.3389\/FNINS.2019.00601 (2019).","journal-title":"Front. Neurosci."},{"issue":"5-6","key":"49537_CR46","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/21678421.2021.2007952","volume":"23","author":"G Sferruzza","year":"2022","unstructured":"Sferruzza, G. et al. Neurofilament light chain as a biological marker for amyotrophic lateral sclerosis: A meta-analysis study. Amyotroph. Lateral Scler. Frontotemporal Degener. 23(5\u20136), 446\u2013457. https:\/\/doi.org\/10.1080\/21678421.2021.2007952 (2022).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"issue":"4","key":"49537_CR47","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","volume":"19","author":"M Benatar","year":"2022","unstructured":"Benatar, M. et al. Design of a randomized, placebo-controlled, phase 3 trial of Tofersen initiated in clinically presymptomatic SOD1 variant carriers: The ATLAS study. Neurotherapeutics 19(4), 1248\u20131258. https:\/\/doi.org\/10.1007\/s13311-022-01237-4 (2022).","journal-title":"Neurotherapeutics"},{"issue":"1","key":"49537_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-022-10220-0","volume":"12","author":"E Abati","year":"2022","unstructured":"Abati, E. et al. Clinical and genetic features of a cohort of patients with MFN2-related neuropathy. Sci. Rep. 12(1), 6181. https:\/\/doi.org\/10.1038\/S41598-022-10220-0 (2022).","journal-title":"Sci. Rep."},{"issue":"21","key":"49537_CR49","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1093\/hmg\/ddz199","volume":"28","author":"A Kagiava","year":"2019","unstructured":"Kagiava, A. et al. Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. Hum. Mol. Genet. 28(21), 3528\u20133542. https:\/\/doi.org\/10.1093\/hmg\/ddz199 (2019).","journal-title":"Hum. Mol. Genet."},{"issue":"19","key":"49537_CR50","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1093\/hmg\/ddw258","volume":"25","author":"F Rizzo","year":"2016","unstructured":"Rizzo, F. et al. Selective mitochondrial depletion, apoptosis resistance, and increased mitophagy in human Charcot-Marie-Tooth 2A motor neurons. Hum. Mol. Genet. 25(19), 4266\u20134281. https:\/\/doi.org\/10.1093\/hmg\/ddw258 (2016).","journal-title":"Hum. Mol. Genet."},{"issue":"9","key":"49537_CR51","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1021\/ACS.JPROTEOME.8B00022","volume":"17","author":"V Phan","year":"2018","unstructured":"Phan, V. et al. Characterization of Na\u00efve and Vitamin C-Treated Mouse Schwann Cell Line MSC80. J Proteome Res. 17(9), 2925\u20132936. https:\/\/doi.org\/10.1021\/ACS.JPROTEOME.8B00022 (2018).","journal-title":"J Proteome Res."},{"issue":"3","key":"49537_CR52","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/J.NEURES.2005.08.006","volume":"53","author":"H Saito","year":"2005","unstructured":"Saito, H. et al. Specific expression of an HNK-1 carbohydrate epitope and NCAM on femoral nerve Schwann cells in mice. Neurosci. Res. 53(3), 314\u2013322. https:\/\/doi.org\/10.1016\/J.NEURES.2005.08.006 (2005).","journal-title":"Neurosci. Res."},{"issue":"2","key":"49537_CR53","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/S00441-012-1493-6","volume":"350","author":"L Mensching","year":"2012","unstructured":"Mensching, L. et al. Local substitution of GDF-15 improves axonal and sensory recovery after peripheral nerve injury. Cell. Tissue. Res. 350(2), 225\u2013238. https:\/\/doi.org\/10.1007\/S00441-012-1493-6 (2012).","journal-title":"Cell. Tissue. Res."},{"issue":"11","key":"49537_CR54","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1515\/cclm-2022-0135","volume":"60","author":"P Welsh","year":"2022","unstructured":"Welsh, P. et al. Reference Ranges for GDF-15, and Risk Factors Associated With GDF-15, in a Large General Population Cohort. Clin Chem Lab Med. 60(11), 1820\u20131829 (2022).","journal-title":"Clin Chem Lab Med."},{"issue":"6","key":"49537_CR55","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/jcsm.12823","volume":"12","author":"J Alcazar","year":"2021","unstructured":"Alcazar, J. et al. Changes in systemic GDF15 across the adult lifespan and their impact on maximal muscle power: The Copenhagen Sarcopenia Study. J. Cachexia Sarcopenia Muscle 12(6), 1418\u20131427 (2021).","journal-title":"J. Cachexia Sarcopenia Muscle"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49537-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49537-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49537-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:27:29Z","timestamp":1779780449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49537-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["49537"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-49537-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16259"}}